Gut Talk

In this episode, hosts Sameer Berry, MD, and William Chey, MD, speak with ACG president-elect, Costas Kefalas, MD, MMM, FASGE, about challenges facing gastroenterologists as well as his goals and initiatives for his upcoming presidential year. ·       How did you become interested in medicine, and who were your early influences? 2:46 ·       Kefalas on earning multiple degrees and being a lifelong learner. 7:30 ·       Can you talk about gastroenterologists engaging in alternative career strategies like locums tenens? 17:33 ·       What are the biggest challenges facing gastroenterologists? 20:11 ·       What is the college's perspective on AI governance and safety within GI? 24:44 ·       Kefalas discusses priorities and initiatives for his upcoming presidential year at the American College of Gastroenterology. 32:58 We'd love to hear from you! Send your comments/questions to [email protected]. Follow us on X @HealioGastro @sameerkberry @umfoodoc. References: DeCamp, M et al. Ann Intern Med. 2026;doi:10.7326/ANNALS-26-01792. Berry and Chey report no financial disclosures. Kefalas reports he is on the advisory board for Brain Tree and GI Health Foundation.

In this special crossover episode, Tuesday Night IBS co-founder Jeffrey Roberts, MSEd, BSc, is joined by William D. Chey, MD, Lin Chang, MD, Kate Scarlata, MPH, RDN, LDN, and Amanda Lynett, MS, RDN, at the FOOD is the Main Course conference. ·       How did you manage the diet paradigm shift for managing care in GI conditions? 2:28 ·       How did witnessing the use of multidisciplinary treatment teams change your clinical practice? 15:05 ·       What was it like to manage the unique emotional toll in your career without burning out?  26:13 ·       What advice do you have for residents and fellows in GI? 43:36 ·       What core values do you hope others have learned from your leadership roles? 58:06 We'd love to hear from you! Send your comments/questions to [email protected]. Follow us on X @HealioGastro, @sameerkberry and @umfoodoc. For more Tuesday Night IBS, be sure check out TuesdayNightIBS.com and to follow and subscribe to their podcast.   References: ·       Drossman DA. Gastroenterology. 2001;doi:10.1053/gast.2001.28976. ·       Khan S, et al. Nat Rev Gastroenterol Hepatol. 2010;doi:10.1038/nrgastro.2010.137.   Chang reports consulting for Ardelyx, Atmo, Eli Lilly & Co., FoodMarble, GSK, Ironwood Pharmaceuticals and Ono Pharmaceutical; receiving speaking fees from Bausch Health; receiving research grants from AnX Robotica and Ironwood; serving on the Rome Foundation board of directors; and having unvested stock options with FoodMarble, ModifyHealth, PICO Health and Trellus Health. Scarlata reports having stock options with Verve Market, Epicured LLC and Fody Foods and receiving financial support from Ardelyx, Salix pharmaceuticals, Orgain and Activia. Chey, Lynett and Roberts report no relevant financial disclosures.   Chang is professor of medicine and vice chief of the Vatche & Tamar Manoukian Division of Digestive Diseases at David Geffen School of Medicine at UCLA. Lynett is the lead registered dietitian with the division of gastroenterology and hepatology at the University of Michigan and co-director of the Food The Main Course conference. Roberts is a patient advocate and creator of the first website for IBS sufferers. He is the co-founder of Tuesday Night IBS. Scarlata is a U.S.-based dietitian with over 30 years of experience. Her expertise is in gastrointestinal disorders and food intolerance.

In this episode, hosts Sameer Berry, MD, and William Chey, MD, speak with Sarah Enslin, PA-C, Vivek Kaul, MD, and Amy Stewart, CRNP, about the benefits of introducing advanced practice providers in practice and how to help them succeed. ·       How can advanced practice providers, or APPs, help overcome access barriers in gastroenterology? 6:54 ·       How can we effectively onboard APPs? 10:24 ·       Is ACG's APP Academy for Clinical Excellence accounting for the fact that different specialties and practices have different requirements? 18:21 ·       What models have worked well for deploying APPs into GI practices? 24:32 ·       What strategies are most effective for APP retention? 29:07 ·       How can we improve professional development for APPs? 42:14 We'd love to hear from you! Send your comments/questions to [email protected]. Follow us on X @HealioGastro, @sameerkberry and @umfoodoc.  Berry and Chey report no financial disclosures. Stewart reports financial relationships with AbbVie, Ardelyx, Celltrion, Cristcot, Eli Lilly & Co, Exact Sciences, Genentech, Johnson & Johnson, Merck, Mindset Health (Nerva), Nestle Health Science, Pfizer, Phathom Pharmaceuticals, Prometheus Laboratories, Regeneron, Salix Pharmaceuticals, Sanofi and Takeda Pharmaceuticals. Healio could not confirm relevant financial disclosures for Enslin and Kaul at the time of publication.

In a special episode recorded live on Capitol Hill, host William Chey, MD, speaks with Congresswoman Debbie Dingell about current challenges facing public health and policy issues surrounding access, advocacy and physician burnout. ·       When thinking about health care legislation, what value do you place on preventing disease over treating it? 2:46 ·       Why can't we get a permanent fix for telehealth benefits? 8:44 ·       Do you think there is any hope for passing the Specialty Physicians Advancing Rural Care (SPARC) Act? 10:43 ·       Chey and Dingell discuss health care disparities and incentivizing physicians to practice in rural areas. 11:55 ·       Chey and Dingell discuss NIH research. 15:47 ·       What can we do to get legislation like the Safe Step Act across the finish line? 21:45 We'd love to hear from you! Send your comments/questions to [email protected]. Follow us on X @HealioGastro @sameerkberry @umfoodoc. Reference: ·        Chey WD. Biomedical research in America: The corrosive effects of uncertainty. ACG Magazine. 2026;10(2):4-5. Chey and Dingell report no financial disclosures. Debbie Dingell represents Michigan's 6th District in the U.S. House of Representatives.

In this episode, Lin Chang, MD, and Jan Tack, MD, PhD, discuss the history and evolution of Rome criteria, developing guidelines for multifactorial disorders in Rome V and more. ·       Lin Chang, MD, and Jan Tack, MD, PhD 1:04 ·       How has the Rome Foundation evolved over the last ten years? 4:26 ·       What are the Rome criteria, and why should clinicians care about them? 7:20 ·       How did these guidelines become the Rome criteria? 10:32 ·       What is the timeline of developing these criteria? 12:35 ·       Can you tell us about how the Rome Foundation got to the name "DGBI", and why it makes sense for multifactorial conditions? 22:22 ·       What are the highlights and most important changes from Rome V?  26:38 ·       How will this information be disseminated so clinicians can learn about it? 34:22 ·       What lessons did you learn from the Rome V process? 37:40 ·       What's next for the Rome Foundation? 40:04 Lin Chang, MD, is professor of medicine and vice chief of the Vatche and Tamar Manoukian Division of Digestive Diseases at David Geffen School of Medicine at UCLA. Jan Tack, MD, PhD, is president of the Rome Foundation. He also serves as professor of medicine at KU Leuven and chief of the division of gastroenterology and hepatology at Leuven University Hospitals. We'd love to hear from you! Send your comments/questions to [email protected]. Follow us on X @HealioGastro @sameerkberry @umfoodoc. Disclosures: Chey and Tack report no financial disclosures. Chang reports consulting roles with Ardelyx, Atmo, Eli Lilly & Co., FoodMarble, GSK, Ironwood Pharmaceuticals and Ono Pharmaceutical; speaking fees from Bausch Health; research grants from AnX Robotica and Ironwood; serving on the Rome Foundation Board of Directors; and having unvested stock options with FoodMarble, ModifyHealth, PICO Health and Trellus Health. Reference: ·        Drossman DA, et al. Gastroenterology. 2026;doi:10.1053.j.gastro.2026.02.014.